Lucas Montarce Takes on CFO Role at Eli Lilly
Eli Lilly and Company (NYSE: LLY) has announced a significant leadership change with the appointment of Lucas Montarce as the new executive vice president and chief financial officer. Montarce's journey with Lilly began in 2001, and throughout his tenure, he has accumulated extensive experience in various finance leadership positions, showcasing his skills and dedication to the company.
Montarce's Rich Experience at Lilly
Prior to stepping into his current role, Montarce held several prominent positions within the organization. He served as the group vice president, corporate controller, and chief financial officer of Lilly Research Laboratories. Additionally, he was the vice president of finance and CFO for Lilly International, as well as the global CFO of Elanco Health. Most recently, Montarce was the president and general manager for operations in a specific regional hub, demonstrating his ability to lead effectively in diverse environments.
Commitment to Vision and Leadership
In his new role, Montarce has expressed a strong commitment to ensuring a solid financial foundation for Lilly, with the goal of driving the company toward ongoing success. "I am dedicated to building on our strong financial base and helping to foster continued success as we expand our global presence," Montarce stated. His enthusiasm for the company's mission is evident as he anticipates working closely with the executive team and his finance colleagues.
Insights from the CEO
David A. Ricks, chair and CEO of Eli Lilly and Company, shared his thoughts on Montarce's appointment. Ricks noted that the search for a new CFO was thorough and encompassed various industries. He expressed confidence in Montarce's abilities, stemming from their decade-long partnership, which highlights Montarce's drive, curiosity, and integrity. Ricks remarked, "Developing leadership talent has always been a strength for Lilly, and Lucas has thrived in a wide variety of roles of increasing scope and impact." This reinforces the trust placed in Montarce as he takes on the responsibility of leading Lilly's financial strategies.
About Eli Lilly and Company
Lilly is a global healthcare company focused on transforming scientific advancements into healing. With over 150 years of experience, their pioneering work has positively impacted more than 51 million people around the world. By integrating biotechnology and genetic medicine, Lilly continues to push the limits of medical science, addressing significant health challenges. Their innovative strategies include redefining diabetes care, tackling obesity, and advancing treatments for Alzheimer's disease and critical immune disorders.
Commitment to Accessibility and Diversity
As a company dedicated to improving lives, Lilly places a high priority on accessibility and affordability in its products. They understand the importance of diversity in clinical trials and strive to develop solutions that cater to a broad range of populations. This commitment not only enriches their research but also ensures that their medicines reach those in need, reinforcing their humanitarian efforts.
Frequently Asked Questions
Who is the new CFO of Eli Lilly?
Lucas Montarce has been appointed as the new CFO of Eli Lilly and Company.
What roles did Montarce hold before becoming CFO?
Before his promotion, Montarce served in several key finance leadership roles, including CFO for various divisions of Lilly and the Global CFO of Elanco Health.
What is Lilly's mission?
Lilly aims to turn scientific advancements into healing, continuously seeking to make life better for over 51 million people globally.
What are some challenges Lilly is addressing?
Lilly focuses on redefined diabetes care, obesity treatment, Alzheimer's disease, immune system disorders, and difficult-to-treat cancers.
How does Lilly ensure medication accessibility?
Lilly is committed to making its medicines accessible and affordable, while also ensuring diversity in clinical trials.
